Description
The debate identified syndecan-1 as a novel target for glycocalyx regeneration but noted extremely low druggability scores. The specific molecular approaches for selective upregulation and the risk of disrupting glycocalyx homeostasis remain major unresolved challenges.
Source: Debate session sess_SDA-2026-04-01-gap-v2-ee5a5023 (Analysis: SDA-2026-04-01-gap-v2-ee5a5023)